Afonso Arsénio holds a B.Sc. in Genetics and Biotechnology from the University of Trás-os-Montes and Alto Douro (UTAD). He is currently pursuing a Master’s degree in Technological and Comparative Molecular Genetics at UTAD and is conducting his dissertation project at the Life and Health Sciences Research Institute (ICVS), University of Minho. He is being supervised within the Translational Neurogenetics team by Dr. Joana Sousa and Dr. Daniela Monteiro. The project focuses on developing and validating a cell-based high-throughput screening assay for expanded ataxin-3 degradation.
Afonso Arsénio holds a B.Sc. in Genetics and Biotechnology from the University of Trás-os-Montes and Alto Douro (UTAD). He is currently pursuing a Master’s degree in Technological and Comparative Molecular Genetics at UTAD and is conducting his dissertation project at the Life and Health Sciences Research Institute (ICVS), University of Minho. He is being supervised within the Translational Neurogenetics team by Dr. Joana Sousa and Dr. Daniela Monteiro. The project focuses on developing and validating a cell-based high-throughput screening assay for expanded ataxin-3 degradation.
Departing from previous work in which we developped cellular and animal models of Machado-Joseph disease, a neurodegenerative disorder caused by expansion of a polyglutamine tract in the protein ataxin-3 (ATXN3)…
